Partnering with us, you will gain:
Leading Technology:
Cutting-edge needle-free injection solutions, capable of delivering high-viscosity and sensitive drugs with precision and stability.
Practical Implementation:
Mature automated production lines, rapidly deployable and compliant with international quality standards, adaptable to different drug types and dosages.
Collaborative Value:
Optimize drug utilization efficiency, enhance patient compliance, and create differentiated competitive advantages to strengthen market position.
Contact UsAbout Us
Beijing QS Medical Technology Co., Ltd. ("Quinovare") is a global leader in innovative needle-free drug delivery solutions.
Since 2007, we have been dedicated to advancing fluid-based delivery technologies that provide patients with safer, more effective, and more comfortable treatment options.
Our portfolio includes needle-free safety injectors, smart injection systems, and drug–device combination platforms, enabling precise intradermal, subcutaneous, and intramuscular delivery. These solutions are being applied to insulin, HGH, incretin, vaccines, nucleic acid medicines, emergency medicine, and pain management—demonstrating significant advantages and vast market potential.
We are committed to driving the future of needle-free therapeutics, shaping a new standard of care for patients worldwide.
from
Nature to Future
Accuracy｜Safety｜Efficiency
Mission
Absorbing medication naturally, enhancing life's fundamental ability to regenerate.
Vision
Needle-free treatment makes the world a better place.
2007
Quinovare was established, and QS-M needle free injector was successfully developed.
2012
GMP system establishment.
2014
The insulin indication was approved by the NMPA. Recognized as a national high-tech enterprise.
2017
2020
The needle-free insulin trial was accepted for publication in EClinicalMedicine of The Lancet and was presented at the 2019 American Diabetes Association meeting.
Operation guideline for Quinovare needle-free insulin Injection issued by Chinese Nursing Association.
2021
The indication for growth hormone was approved.
Needle-free Injections included in Type I Diabetes Management Guidelines.
2022
The needle-free mRNA vaccine study published in Nano Today.
2023
The indication for incretin was approved by the NMPA.
2024
To build a customized platform for innovative drug delivery devices that empower pharmaceutical enterprises.
2025
Launched the world's first cartridge-inserted needle-free device in January.
To establish a customized platform for prefilled needle-free injection device.
